Assessment of minimal residual disease in childhood non-hodgkin lymphoma by polymerase chain reaction using patient-specific primers

J Pediatr Hematol Oncol. 2003 Feb;25(2):109-13. doi: 10.1097/00043426-200302000-00005.

Abstract

A feasibility study was undertaken to identify patient-specific primers (PSPs) from childhood non-Hodgkin lymphoma (NHL) specimens to detect minimal residual disease (MRD). Eleven tumor specimens were amplified using immunoglobulin heavy chain and T-cell receptor primers to identify PSPs, which were then used to evaluate staging/follow-up specimens. Disease was detected in 19 of 21 staging and 16 of 17 follow-up specimens. Among seven patients in remission by 1 month, PSPs identified MRD in follow-up specimens. This study demonstrated the feasibility of PSPs to identify disease in staging and follow-up specimens, which could be used to develop strategies for MRD analysis in a larger setting.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Burkitt Lymphoma / diagnosis
  • Burkitt Lymphoma / genetics
  • Child
  • Child, Preschool
  • DNA Primers
  • DNA, Neoplasm / analysis*
  • Feasibility Studies
  • Female
  • Genes, T-Cell Receptor delta
  • Genes, T-Cell Receptor gamma
  • Humans
  • Immunoglobulin Heavy Chains / genetics
  • Infant
  • Lymphoma, Non-Hodgkin / diagnosis*
  • Lymphoma, Non-Hodgkin / genetics*
  • Lymphoma, T-Cell / diagnosis
  • Lymphoma, T-Cell / genetics
  • Male
  • Neoplasm, Residual / diagnosis
  • Neoplasm, Residual / genetics
  • Polymerase Chain Reaction / methods*

Substances

  • DNA Primers
  • DNA, Neoplasm
  • Immunoglobulin Heavy Chains